Oppenheimer analyst Jay Olson raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $650 from $600 and keeps an Outperform rating on the shares. The firm is encouraged by recent updates including several presentations at AASLD that strengthen Rezdiffra’s profile and increase its enthusiasm for commercial opportunities in F2-F3 plus F4c patients.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals price target raised to $640 from $580 at Truist
- Paulson exits Iamgold, boosts Bausch Health in Q3
- Optimistic Buy Rating for Madrigal Pharmaceuticals Driven by Strong Drug Performance and Strategic European Expansion
- Madrigal Pharmaceuticals price target raised to $587 from $526 at Canaccord
- Madrigal price target raised to $568 from $500 at H.C. Wainwright